Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Jarushka Naidoo(Johns Hopkins University), David B. Page(Providence Portland Medical Center), Bob T. Li(Memorial Sloan Kettering Cancer Center), Louise C. Connell(Memorial Sloan Kettering Cancer Center), Katja Schindler(Medical University of Vienna), Mario E. Lacouture(Memorial Sloan Kettering Cancer Center), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center)
Annals of Oncology
September 14, 2015
10.1093/annonc/mdv383
Cited by 1,460Open Access
Full Text

Abstract

Related Papers

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al.|New England Journal of Medicine|2015|9.4k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles, Joseph P. Eder, Gregg Fine et al.|Nature|2014|2.4k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas, Igor Puzanov, Reinhard Dummer et al.|The Lancet Oncology|2015|1.6k
Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor
Amit A. Lugade, James P. Moran, Scott A. Gerber et al.|The Journal of Immunology|2005|940
Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab
Jeffrey S. Weber, Reinhard Dummer, Veerle de Pril et al.|Cancer|2013|461